In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline

Eravacycline (TP-434) Is ActiveIn Vitroagainst Biofilms Formed by Uropathogenic Escherichia coli

(2015) Trudy H. Grossman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Eravacycline against Escherichia coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype

(2015) James R. Johnson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Eravacycline (TP-434) Is Efficacious in Animal Models of Infection

(2015) Trudy H. Grossman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections

(2015) Matteo Bassetti et al.   Current Opinion in Critical Care

Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA

(2015) Alpesh N Amin et al.   Future Microbiology

A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens

(2015) Karen Bush   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Investigational Agents for the Treatment of Gram-Negative Bacterial Infections: A Reality Check

(2015) Karen Bush   ACS Infectious Diseases

Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City

(2014) Marie Abdallah et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In VitroSusceptibility of Characterized β-Lactamase-Producing Strains Tested with Avibactam Combinations

(2014) Henry Li et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Global Challenge of Carbapenem-Resistant Enterobacteriaceae in Transplant Recipients and Patients With Hematologic Malignancies

(2014) M. J. Satlin et al.   CLINICAL INFECTIOUS DISEASES

Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?

(2014) Malcolm GP Page et al.   CURRENT OPINION IN PHARMACOLOGY

Challenges in the Management of Infections due to Carbapenem-Resistant Enterobacteriaceae

(2014) Dimitri M. Drekonja et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections

(2013) Joseph S. Solomkin et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens

(2013) J. A. Sutcliffe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Contemporary Diversity of β-Lactamases among Enterobacteriaceae in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β-Lactamase Groups

(2013) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic

(2012) Trudy H. Grossman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Detection systems for carbapenemase gene identification should include the SME serine carbapenemase

(2012) Karen Bush et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Combating Antimicrobial Resistance: Policy Recommendations to Save Lives

(2011)   CLINICAL INFECTIOUS DISEASES

Detection of 2 SME-1 carbapenemase-producing Serratia marcescens in Detroit

(2011) Marilynn R. Fairfax et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Multiplex PCR for detection of acquired carbapenemase genes

(2011) Laurent Poirel et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Molecular Epidemiology of CTX-M-Producing Escherichia coli Isolates at a Tertiary Medical Center in Western Pennsylvania

(2009) H. E. Sidjabat et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY